Antibody drug conjugates (ADCs) are an innovative biopharmaceuticals that combine the highly targeting specificity of antibodies with potent cytotoxic drug molecules linked through stable chemical linkers to provide superior therapeutic efficacy toward targeted diseases. ADC therapeutics comprise a new class of pharmaceuticals that provide both target specificity and therapeutic efficacy that may not be achieved by antibody or drug alone. Three are three major components in an effective ADC drug:

• A highly target specific monoclonal antibody that is able to recognize specific disease cells;
• A chemical linker that is stable in circulation but can release cytotoxic agents upon entering targeted cells;
• A highly potent cytotoxic agent that is able to induce target cell death upon enter the targeted tissues.

In past several decades, Nanocs has become an expert in ADC drug development. Our experience in the area of molecule synthesis, linker design and bioconjugation enables our customers to fully utilize our expertness in the development of their specific ADC drug candidates. Please fell free to contact us if you need any advice in your ADC drug development.

Related Products:

SnapLink linkage agents

• Thiol-ether formation maleimide linkers;
• Cleavable disulfide formation linkers;
• Acid-labile linkage agents;
• Peptido linkers;

Cytotoxic agents for ADC development